KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Short-term Investments: 2018-2023

Historic Short-term Investments for Esperion Therapeutics (ESPR) over the last 3 years, with Mar 2023 value amounting to $17.4 million.

  • Esperion Therapeutics' Short-term Investments fell 74.42% to $17.4 million in Q1 2023 from the same period last year, while for Mar 2023 it was $17.4 million, marking a year-over-year decrease of 74.42%. This contributed to the annual value of $42.1 million for FY2022, which is 16.56% down from last year.
  • According to the latest figures from Q1 2023, Esperion Therapeutics' Short-term Investments is $17.4 million, which was down 58.59% from $42.1 million recorded in Q4 2022.
  • Over the past 5 years, Esperion Therapeutics' Short-term Investments peaked at $68.1 million during Q1 2022, and registered a low of $2.2 million during Q2 2020.
  • Its 3-year average for Short-term Investments is $45.2 million, with a median of $46.3 million in 2021.
  • Data for Esperion Therapeutics' Short-term Investments shows a maximum YoY crashed of 91.64% (in 2020) over the last 5 years.
  • Over the past 5 years, Esperion Therapeutics' Short-term Investments (Quarterly) stood at $34.7 million in 2019, then crashed by 91.64% to $2.2 million in 2020, then reached $50.4 million in 2021, then declined by 16.56% to $42.1 million in 2022, then crashed by 74.42% to $17.4 million in 2023.
  • Its last three reported values are $17.4 million in Q1 2023, $42.1 million for Q4 2022, and $29.9 million during Q3 2022.